SCHEMBL21751067

SCHEMBL21751067

O=C1CCC(n2nnc3ccc(Br)cc3c2=O)C(=O)N1

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 18/20 0.54
DDB1 Q16531 16/20 0.50
IKZF3 Q9UKT9 4/20 0.42
ALDH1A1 P00352 1/20 0.39
CHRM2 P08172 1/20 0.39
OPRM1 P35372 1/20 0.39
CYP1A2 P05177 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
BCL2L11 O43521 1/20 0.38
BCL2 P10415 1/20 0.38
MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21751118 0.87 CRBN (0.55) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL21751098 0.86 CRBN (0.56) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL29791185 0.86 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL30291340 0.86 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL24233170 0.86 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL23534466 0.86 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL21751104 0.86 CRBN (0.54) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL30241763 0.86 CRBN (0.56) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL31426262 0.85 CRBN (0.52) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL31425845 0.83 CRBN (0.52) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110621664-B Novel piperidine-2, 6-dione derivatives and uses thereof 韩国化学研究院 2023-08-01 CN claimed
EP-3623366-B9 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF KOREA RES INST CHEMICAL TECH (KR) 2022-06-15 EP claimed
EP-3623366-B1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF KOREA RES INST CHEMICAL TECH (KR) 2022-01-19 EP claimed
US-11192878-B2 Piperidine-2,6-dione derivative and use thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2021-12-07 US claimed
EP-3623366-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2020-03-18 EP claimed
US-20200062730-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2020-02-27 US claimed
CN-110621664-B Novel piperidine-2, 6-dione derivatives and uses thereof 韩国化学研究院 2023-08-01 CN disclosed
WO-2023116835-A1 MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON 苏州开拓药业股份有限公司 2023-06-29 WO disclosed
EP-3623366-B9 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF KOREA RES INST CHEMICAL TECH (KR) 2022-06-15 EP disclosed
US-20220105188-A1 TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-04-07 US disclosed
EP-3623366-B1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF KOREA RES INST CHEMICAL TECH (KR) 2022-01-19 EP disclosed
US-11192878-B2 Piperidine-2,6-dione derivative and use thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2021-12-07 US disclosed
WO-2020162725-A1 TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT 한국화학연구원 2020-08-13 WO disclosed
EP-3623366-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2020-03-18 EP disclosed
US-20200062730-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2020-02-27 US disclosed
CN-110621664-A Novel piperidine-2, 6-dione derivatives and uses thereof 韩国化学研究院 2019-12-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220105188-A1 TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT EED, VHL, CUL1 CRBN 4/4885DDB1 1206/4885IKZF3 360/4885
US-20200062730-A1 NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF CRBN, PDCD11, CD47 CRBN 1/4885DDB1 153/4885IKZF3 969/4885
US-11192878-B2 Piperidine-2,6-dione derivative and use thereof CRBN, PDCD11, CD47 CRBN 1/4885DDB1 196/4885IKZF3 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.